Diabetes Mellitus, Type 2

The supplied grounding supports a multifactorial basis rather than a single cause. Obesity-linked insulin resistance is implicated, and hypoadiponectinemia has been described as playing an important causal role in insulin resistance and type 2 diabetes. The gut microbiome is also linked to the disease in mechanistic reviews, suggesting contributions from host-microbe interactions.

The core biological feature is insulin resistance, with compensatory hyperinsulinemia early in the disease. The literature grounding also points to altered insulin secretion, disrupted energy and glucose metabolism, and changes in signaling pathways, with oxidative stress and gut microbiome-related effects implicated in disease biology. Adipokine signaling, including adiponectin and its receptors, is described as part of the antidiabetic regulatory network that is downregulated in obesity-linked insulin resistance.

Obesity is explicitly associated with type 2 diabetes in the supplied definition and reviews. Metabolic dysfunction and obesity-linked insulin resistance are supported risk contexts, and hypoadiponectinemia is described as contributing to disease development. The grounding also links the disease with diet and gut microbiome deviations, but does not support more specific risk estimates.

Management is centered on lifestyle management and diabetes self-management education and support, with weight-loss efforts emphasized for patients with obesity. Drug therapy includes glucose-lowering medications such as metformin, GLP-1 receptor agonists, and SGLT2 inhibitors, with GLP-1 receptor agonists or SGLT2 inhibitors highlighted for patients with cardiovascular disease. The grounding also supports broader medication and surgical interventions for weight loss in appropriate patients, but does not provide regimen-level detail.